High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma

Don M. Benson, Patrick J. Elder, Thomas S. Lin, William Blum, Sam Penza, Belinda Avalos, Edward Copelan, Sherif S. Farag

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) has improved response rates and survival for patients with multiple myeloma (MM). We report a single-institution experience using two conditioning regimens, busulfan, cyclophosphamide, and etoposide (BCV) or high-dose melphalan (HDM). Between July 1992 and August 2003, 110 patients with MM (median age = 56.1) underwent HDC with ASCT using either BCV (n = 62) or HDM (n = 48) in sequential cohorts as the preparative regimen. Overall response rates, progression-free survival, and median overall survival were similar. BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM.

Original languageEnglish (US)
Pages (from-to)1069-1075
Number of pages7
JournalLeukemia Research
Volume31
Issue number8
DOIs
StatePublished - Aug 2007
Externally publishedYes

Keywords

  • Autologous transplantation
  • Conditioning regimens
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma'. Together they form a unique fingerprint.

  • Cite this